Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early antiviral therapy in COVID-19 with favipiravir and/or lopinavir/ritonavir
2020-002106-68Phase 2Unknown
- Sponsor
- UCL Comprehensive Clinical Trials Unit
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of favipiravir and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by UCL Comprehensive Clinical Trials Unit. Primary endpoint: Upper respiratory tract viral load at Day 5. Status: unknown.
02
Drugs
favipiravirlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002106-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002106-68.